High-throughput screening (HTS) has become an important part of drug discovery at most pharmaceutical and many biotechnology companies worldwide, and use of HTS technologies is expanding into new areas. Target validation, assay development, secondary screening, ADME/Tox, and lead optimization are among the areas in which there is an increasing use of HTS technologies. It is becoming fully integrated within drug discovery, both upstream and downstream, which includes increasing use of cell-based assays and high-content screening (HCS) technologies to achieve more physiologically relevant results and to find higher quality leads. In addition, HTS laboratories are continually evaluating new technologies as they struggle to increase their success rate for finding drug candidates. The material in this article is based on a 900-page HTS industry report involving 54 HTS directors representing 58 HTS laboratories and 34 suppliers. (Journal of Biomolecular Screening 2006:864-869) 
INTRODUCTION
A RECENT WORLDWIDE STUDY involving 54 HTS directors representing 58 HTS laboratories and 34 suppliers, titled High Throughput Screening: New Users, More Cell-Based Assays, and a Host of New Tools, 1 documents current HTS successes. Altogether, 104 clinical candidates, leads originally found through the use of HTS technologies, were reported by the HTS directors participating in the study. This is the largest number of clinical candidates to be reported since these industry reports began in 1997. Four products are on the market. The material in this article is based on this 900-page HTS industry report.
EXPANSION
Important trends in HTS include the following.
New users
In 2005, the National Institutes of Health (NIH), as part of the NIH Roadmap for Medical Research, awarded $88.9 million in grants to 9 institutions to use HTS methods for the identification of small molecules that can be used as research tools in drug discovery. In addition, new HTS academic laboratories and government institute laboratories are emerging.
HTS technologies are being adopted beyond the traditional geographic markets of Europe and North America. New and existing HTS laboratories in Asia and the rest of the world are increasing their spending on equipment and consumables for HTS. Today, 50% of the suppliers participating in this study report HTS sales in Asia, up from 35% in 2003.
More cell-based assays
HTS directors anticipate greater use of cell-based assays as a percentage of all assays, with an increase of more than 7 percentage points over a 2-year period ending this year. This will push cell-based assays to an average of 52.6% of all HTS assays. In 2006, more than half of all HTS directors surveyed for this report are using cell-based HCS technologies for some screens. The percentage use of HCS out of all screening was small in 2004 and 2005, about 4% on average, but this percentage use is expected to double by 2006 to 8%. Overall, HTS directors say that the most important new technology affecting the future of HTS is HCS. Although HCS is most often used in secondary screening, in 2006, 44% of the HTS director respondents expect to be using some HCS in primary screening.
A host of new tools
The development and refinement of new technologies are affecting HTS practices. In 2006, more than half of the HTS directors surveyed will be using or seeking new tools to accommodate increasing use of HCS, including instrumentation for imaging, engineered stable cell lines, flexible automated cell culture systems, HCS reagents, automation to increase throughput, assay development services and kits, tools for faster sample preparation, and data analysis and data-handling software. Also, HTS directors are increasing their use of other tools such as label-free assays, cell-based assays, miniaturization, multiplexing, predictive software, automated ion channel or electrophysiology readouts in high throughput, and a host of flexible instrumentation and platform options.
Evolving strategies
Along with the new tools and increased integration, screening strategies are also changing. More HTS laboratories are screening focused libraries and using predictive profiling of compounds and compound cherry-picking. A systems biology approach and the use of pharmacogenomics are increasingly becoming popular. New uses for HTS technologies are emerging such as small interfering RNA and RNA interference research, biomarker research, in vitro ADME/Tox screening and pharmacokinetic characterization, and screening for toxicity and safety. Outsourcing is occurring at all stages but especially in secondary screening. Price sensitivities and strategies to minimize cost while increasing the quality of leads coming from HTS continue to be the main challenges.
SUCCESSES REPORTED
As a measure of success to date, participants were asked to report on the percentage of targets that generated leads in 2004. Because it requires at least 1 year or more to determine whether a hit has become a lead, respondents were asked to report for 2004. Definitions of leads vary widely, so participants were asked to respond using a common definition to obtain comparable data. The definition used in this study is as follows:
A "lead" is defined as a hit confirmed by more than 1 assay in vitro, and if possible in vivo, in a manner that shows biologically relevant activity that correlates to the target. To be a lead, the compound must show evidence that a SAR (structure-activity relationship) can be built around it.
Forty-seven HTS directors reported on the percentage of their targets that have generated leads. The large range of answers, from 0% to 100%, indicates the variation in the HTS laboratories, the types of targets, the challenges, and the processes. The average for all respondents was 50%. Interestingly, the average percentages in the 2000 report and the 2002 report were lower: 44% and 43%, respectively. In the 2003 report, the percentage had jumped to 56%. It appears that the HTS laboratories are maintaining their productivity overall at the 50% level on average. These results are illustrated in Figure 1 .
In this study, HTS laboratories were sorted into 3 groups:
1. high-throughput group, reading 100,000 or more wells per week (29 HTS laboratories represented in this study); 2. medium-throughput group, reading less than 100,000 wells per week (19 HTS laboratories represented in this study); and 3. noncommercial laboratories, academic centers, and government institutes tending to have comparatively low throughput, in the range of 3000 to 7000 wells read per week (10 HTS laboratories represented in this study).
The average percentage of targets generating leads for the high-throughput group is slightly higher than the percentage for the medium-throughput group, and both of these groups have a higher percentage than the averaged noncommercial laboratory percentage, as shown in Table 1 .
To understand the number of leads coming out of HTS overall, directors were asked to provide the number of leads that Figure 2 . The range for the number of leads generated in 2004 by type of HTS laboratory is shown in Table 2 .
The maximum number of leads from any 1 HTS laboratory is 120, whereas the minimum is 0, as shown in Table 2 . In this count, most HTS directors included all leads in a series of leads for 1 target. Several directors reported that they found multiple leads for their targets. The 1 respondent who reported finding 120 leads had 11 targets in 2004 and found an average of 10 to 11 leads in a lead series for each. The numbers of leads are rough estimates for several reasons: individual interpretations of the lead definition, different target types, the counting of lead series per target, and other individual circumstances. The next measure of success is the number of leads originally found through HTS methods that are being tested in humans. Of all the respondents, 26 HTS directors report having HTS leads in clinical trials for testing in humans. These 26 directors report a total of 104 drug candidates originally screened using HTS technologies, as follows:
• 62 drug candidates from 17 high-throughput laboratories, and • 42 drug candidates from 9 medium-throughput laboratories.
The largest number of drug candidates from any one HTS laboratory is 12. Four drug candidates originally screened in an HTS laboratory were reported as having made it to the commercial market: 1 originally screened in 1984, 2 screened in 1989, and 1 screened in 1999. Only drug candidates currently in clinical trials or on the market are counted. Two respondents mentioned several compounds that made it to the clinic but were later dropped during clinical trials. The 104 drug candidates generated by HTS laboratories are listed in Table 3 . This number is up compared to the 2003 study, in which 28 respondents reported 74 drug candidates from HTS. A historical comparison of drug candidates is shown in Figure 3 , and a chart illustrating the current drug candidates by date of the original HTS screen is shown in Figure 4 .
Comments from HTS directors regarding drug candidates originally screened in HTS laboratories now in clinical trials follow.
What is the contribution of HTS? It is the composite of approaches. I would argue that, of those compounds in lead optimization, half of them have a strong HTS component in their discovery. The most advanced compounds are an exception. The quality of leads is better now. We used to screen anything we could get our hands on; now we are more selective. A hit is a reasonable starting point for chemistry. Attrition rates have not gone down as a result of the higher quality compounds because the hurdles get higher.
We have 29 projects to choose from. That gives us a higher success rate because we know a lot about each compound before making the selection of which ones to progress. We moved all 29 forward, but we had to kill programs downstream. Sometimes we are forced to pull projects because we cannot fund development of all of them. We have a selection process. So far, of those that progressed, none have dropped out.
We had a lot more drug candidates than the number I am giving you, maybe 10 more, which made it to clinical trials and then dropped out for the usual reasons. About 15 compounds from 15 screens have made it into the clinic. The attrition rate is high, but the time frame in which drug discovery is done is much more rapid now. Compound libraries are better now than when we first started doing HTS.
We are successful about getting compounds into the clinic. There are only 3 left in the clinic now, but 1 of the dropped compounds might go back into the clinic after reoptimization.
All candidates in phase 2 have been tested in HTS. Some compounds in preclinical development were screened in 2000 through 2002. HTS is one tool that is useful if it is used well. That is a very important concept. It only works as a tool, not a solution.
NEW TECHNOLOGIES AND A PROMISING FUTURE FOR HTS
To understand what are considered the best tools for HTS going forward, the HTS directors were asked to explain their opinions regarding which new tools might help them prioritize their lead candidates more efficiently. The respondents provided a long list of tools. A better predictive tool for ADME/Tox characterization is the predominant need, followed by better in vitro efficacy models and solubility analysis. The respondents were asked to describe any new technologies that they believe will have the largest impact on future HTS. As can be expected, respondents listed numerous new technologies. However, HCS and label-free technologies are the technologies most respondents believe will have the greatest impact on HTS in the future.
To further understand respondents' requirements, the HTS directors were asked to list any of their unmet needs for primary or secondary screening. For primary screening, the most important unmet need is a way to ensure that the target is well-validated, along with strong data analysis tools and high-throughput ion channel assays with electrophysiological readouts. For secondary screening, the most important need is to ensure that the assay is relevant and predictive with connectivity to in vivo results.
Finally, to end the discussion, respondents were asked 1 final question about their vision for the future of HTS. Most respondents see HTS as evolving into a key drug discovery tool that will become more specialized and focused. Respondents' visions for the future are summarized in Table 4 , and selected comments follow. I think HTS groups will be operating in a very mixed mode. Some assays will be screened using traditional HTS. Others will be more focused, screening smarter, leveraging what we already know so we can test fewer compounds and do iterative screening. I might test 5% of the library and then choose the next subset to screen. We might ultimately test only 25% of the library on a given target, but we feel confident that we've mined all the possible hits.
The push is for faster target identification and downstream processing-the integration of HT technologies upstream and downstream.
I think there will be a mix of large-library, focused-library, and specialty screening. HTS groups will need to be very, very There is going to be a huge demand for cherry-picking, since there will be more focused screening and more virtual screens. The burden on compound library management will be very high. I think there will be a lot of little screens that you'll have to fit between the big screens. It will be a big challengemanagement doesn't understand that the assay development time is the same for a big or a little screen.
HTS will get closer to compound profiling, and it will become more interactive with therapeutic and chemistry groups and the hit-to-lead process.
In 5 years, I think we will see more primary cells used in screens. HCS will have its niche. We will learn more about our compound collections through predictive in silico tools. There is likely to be more focused screening and greater success in HTS through decreased attrition and increased quality leads.
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